Miura, Yuji
Sukawa, Yasutaka
Hironaka, Shuichi
Mori, Misuzu
Nishikawa, Kazuhiro
Tokunaga, Shinya
Okuda, Hiroyuki
Sakamoto, Takeshi
Taku, Keisei
Nishikawa, Kazuo
Moriwaki, Toshikazu
Negoro, Yuji
Kimura, Yutaka
Uchino, Keita
Shinozaki, Katsunori
Shinozaki, Hiroharu
Musha, Nobuyuki
Yoshiyama, Hirotsugu
Tsuda, Takashi
Miyata, Yoshinori
Sugimoto, Naotoshi
Shirakawa, Tsuyoshi
Ito, Miki
Yonesaka, Kimio
Yoshimura, Kenichi
Boku, Narikazu
Nosho, Katsuhiko
Takano, Toshimi
Hyodo, Ichinosuke
Funding for this research was provided by:
Taiho Pharmaceutical
Japan Society for the Promotion of Science (JSPS; KAKENHI 26430174)
Article History
Received: 16 December 2016
Accepted: 29 April 2017
First Online: 11 May 2017
Compliance with ethical standards
:
: Yuji Miura received honoraria from Novartis and Kyowa Hakko Kirin. Ichinosuke Hyodo received honoraria from Taiho, Chugai, Daiichi-Sankyo, Yakult-Honsha, and Eli Lilly. Toshikazu Moriwaki received honoraria from Taiho, Chugai, and Takeda and research funding from Taiho, Sanofi, Boehringer Ingelheim, and MSD. Kazuhiro Nishikawa received honoraria from Taiho, Chugai, Yakult, and Ajinomoto. Naotoshi Sugimoto received research funding from Taiho, Daiichi-Sankyo, and Eli Lilly. Kenichi Yoshimura received honoraria from Taiho and Chugai. The remaining authors declare that they have no conflict of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent (biomarker sampling was not mandatory) or a substitute for it was obtained from all patients included in the study, and the ethics committee of each institution approved all study procedures.
Free to read: This content has been made available to all.